Market Research Report

A quick peek into the report

Europe Gene Fusion Testing Market

Analysis and Forecast, 2023-2033

 
Some Faq's

Frequently Asked Questions

•    Companies that manufacture and commercialize consumables required in the testing of genetic abnormal alterations in chromosomes
•    Any new entrant that wants to know where the opportunities lie in the gene fusion testing market
•    Any established player that wants to expand its product portfolio or business in new geographies

The global gene fusion testing market was valued at $255.3 million in 2022 and is anticipated to reach $897.6 million by 2033, witnessing a CAGR of 12.25% during the forecast period 2023-2033.

Gene fusion is used to identify and characterize genetic abnormalities where two or more genes fuse together, often because of chromosomal rearrangements. This diagnostic technique is essential in cancer research and clinical oncology to understand the underlying genetic drivers of tumors and to develop targeted therapies for specific cancer types.

Gene fusion testing is a molecular diagnostic method to identify genetic alterations in cancer cells. It occurs when two genes from different chromosomes fuse, creating a hybrid gene with altered functions. It involves analyzing tumor sample DNA/RNA, using techniques like PCR, FISH, IHC, and NGS, and is valuable in managing various cancers, including NTRK gene fusion.

Gene fusion and fission are opposite processes involving the rearrangement of genetic material. Gene fusion combines two separate genes into one, often leading to the creation of a novel protein. In contrast, gene fission divides a single gene into two or more separate genes, potentially altering their functions or regulation.

Similar Product

You may also like

Gene Fusion Testing Market - A Global and Regional Analysis
Published Year: 2023

Gene Fusion Testing Market - A Global and Regional Analysis: Focus on by Category, Technology, Indic

The global gene fusion testing market was valued at $255.3 million in 2022 and is anticipated...